Le Lézard
Classified in: Science and technology
Subjects: Product/Service, Corporate Social Responsibility, Award

RepRisk releases its Most Controversial Projects of 2018 Report?three of ten projects highlight the Food and Beverage sector's significant exposure to ESG risks


RepRisk's Most Controversial Projects of 2018 Report focuses on the ten projects that were most exposed to ESG (environmental, social, and governance) and business conduct risks last year. The projects ranked in the report are located in both developed and emerging markets, and stem from a range of sectors, while three projects in this year's issue were linked to salmonella or listeria outbreaks.

"Many of the case studies in this report describe a sequence of events that had catastrophic consequences for employees and local communities," said Dr. Philipp Aeby, CEO of RepRisk. "Sadly, the risk incidents faced by nine out of the ten projects were described as 'foreseeable,' or were blamed on negligence.

Our aim is to raise awareness of potential ESG risks, and to encourage companies to take into account such issues systematically in their risk management strategies and processes. RepRisk is the only ESG research provider that covers projects, thereby supporting our clients' due diligence processes."

RepRisk combines Artificial Intelligence (AI) and human analysis to translate big data in 20 languages into curated research and analytics. In addition to over 29,000 projects, more than 110,000 public and private companies are captured on the RepRisk Platform.

Please click here to read the Most Controversial Projects of 2018 Report.

About RepRisk

RepRisk is a global leader and pioneer in data science, specializing in premium ESG and business conduct risk research and quantitative solutions. Since 2006, RepRisk has been leveraging artificial intelligence and curated human analysis to translate big data into actionable business intelligence and risk metrics. With daily-updated data synthesized in 20 languages using a rules-based methodology, RepRisk systematically flags and monitors material ESG risks and violations of international standards that can have reputational, compliance, and financial impacts on a company. Our flagship product, the RepRisk Platform, is the world's largest database of its kind, consisting of 100k+ public and private companies and 25k+ projects of all sizes, in every sector and market. Leading organizations around the world rely on RepRisk as their key due diligence solution to prevent and mitigate ESG and business conduct risks related to their operations, business relationships, and investments.

Learn more at www.reprisk.com and follow on Twitter: www.twitter.com/reprisk.


These press releases may also interest you

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: